Pharming Group (PHGN) Stock Price & Analysis
PHGN Stock Chart & Stats
- Day’s Range
- EUR 1.11 - EUR 1.14
- 52-Week Range
- EUR 0.60 - EUR 1.78
- Previous Close
- EUR 1.10
- Volume
- N/A
- Average Volume (3M)
- 5,426
- Market Cap
- EUR 771.13M
- Enterprise Value
- EUR 596.37M
- Total Cash (Recent Filing)
- EUR 186.42M
- Total Debt (Recent Filing)
- EUR 112.61M
- Price to Earnings (P/E)
- 34.7
- Beta
- 0.47
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- 0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Joenja Growth
Joenja is establishing a meaningful growth engine alongside RUCONEST, with strong year-over-year revenue expansion and rising patient adoption. Continued uptake in APDS can diversify Pharming’s product base and support sustained revenue growth as commercialization reaches more eligible patients.
Geographic And Pediatric Expansion
Expansion into Germany and Japan, together with broader pediatric access in the United States, increases the addressable treated population and commercial reach of Joenja. These label and geographic gains can support durable growth by improving access across markets and patient groups.
Improving Cash Generation
The return to positive operating cash flow and higher liquidity strengthens Pharming’s ability to fund pipeline programs and prelaunch costs internally. Management’s view that no additional financing is needed also indicates greater near-term financial flexibility for executing its strategy.
Bears Say
Earnings Volatility
The recent return to profitability is encouraging, but the prior losses demonstrate that earnings conversion has not yet been consistently durable. Continued variability could limit financial resilience and make future investment capacity more dependent on sustained product performance.
RUCONEST Competitive Pressure
RUCONEST remains a major revenue contributor, yet oral competition is already pressuring U.S. revenue and may create another step-down when a further competitor launches. This raises an ongoing replacement and retention challenge as Joenja must offset erosion.
Leadership Transition
An unresolved CEO transition creates execution and governance uncertainty during a period of product expansion and pipeline investment. Although interim management says strategy remains unchanged, a prolonged search could complicate accountability, external confidence, and long-term strategic continuity.
Pharming Group News
PHGN FAQ
What was Pharming Group’s price range in the past 12 months?
What is Pharming Group’s market cap?
When is Pharming Group’s upcoming earnings report date?
How were Pharming Group’s earnings last quarter?
Is Pharming Group overvalued?
Does Pharming Group pay dividends?
What is Pharming Group’s EPS estimate?
How many shares outstanding does Pharming Group have?
What happened to Pharming Group’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pharming Group?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kenneth Lynard
- Employees
- 407
- Website
- www.pharming.com
- Address
- Darwinweg 24, Leiden, ZH, 2333 CR, NL
Pharming Group (PHGN) Earnings & Revenues
PHGN Company Deck
PHGN Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by 21% third-quarter revenue growth, 89% operating profit growth, strong Joenja momentum, RUCONEST demand stabilization, positive genetic PID data, improving cash generation, and lower full-year operating expense guidance. The main challenges were the approximately 3% expected full-year decline in RUCONEST U.S. revenue, inventory-related timing effects, manufacturing inventory impairments, the ongoing CEO search, and the need to complete FALCON enrollment.
View all DE:PHGN earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 12 | 2 | 8 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 10 | 0 | 2 |
